

I am writing on behalf of NHS Berkshire East (now NHS Berkshire Cluster), as a named consultee, in response to the NICE ACD for Rivoroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation. I would agree with the initial findings from the ACD to not recommend the treatment and agree with the points made in the letter submitted to you from CSAS.

I would echo the views that the cost of warfarin has been estimated as too high by the manufacturer as we currently spend approximately £310,000 on warfarin and associated testing for the Berkshire East population of approximately 376,500 (based on figures from 2010/11), unfortunately it is not easy to break down the warfarin figures for those being treated for AF but it is considerably less than the estimated £2.8 million that the cost of rivaroxaban for AF patients eligible for treatment (based on rivaroxaban costs of £766.50/year).

Yours sincerely,

NHS Berkshire East

Primary Care Commissioning Office
2nd Floor,
King Edward VII Hospital
Windsor
SL4 3DP